person · Reporting owner
Borie Dominique Christian
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Chief Medical Officer · Head of Research & Development | July 13, 2026 | July 15, 2026 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | See Remarks | February 07, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date July 13, 2026 · Filed July 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,500 |
Reported balance
After 2026-07-13 transaction · row 1
1 source rowRow 1 · 2026-07-13 · Grant · Acquired 31,500 · Balance 31,500 F1: Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.92 · Expires 2036-07-13 | Direct | 63,000 |
Reported balance
After 2026-07-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-13 · Grant · Acquired 63,000 · Balance 63,000 F2: The stock option becomes exercisable in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date.
F2: The stock option becomes exercisable in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date.
Kyverna Therapeutics, Inc.
Report date February 07, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Borie Family Trust, dated November 9, 2005 | 449,210 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 449,210 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.42 · Expires 2032-05-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: 25% of the original number of shares subject to the option vested on May 6, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2033-07-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2033-11-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the original number of shares subject to the option vested on May 6, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2026 Filed Jul 15, 2026 22:59 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (Right to Buy) · Derivative | 63,000 | $0.00 Strike: $30.92 | $0.00 |
DisclosureSEC source: 0002008790-26-000006 · form4-07152026_100742.xml · derivative · entry 2 Borie Dominique Christian · CIK 0002008790 · Chief Medical Officer · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2036-07-13 F2 · derivative.exercise_date: The stock option becomes exercisable in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date. Read SEC document |
| July 13, 2026 Filed Jul 15, 2026 22:59 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0002008790-26-000006 · form4-07152026_100742.xml · nonDerivative · entry 1 Borie Dominique Christian · CIK 0002008790 · Chief Medical Officer · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 F1 · shares: Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.